Type 2 diabetes mellitus (DM2) affects a 13.8% of the Spanish population1 and its prevalence is expected to increase in the future.2 The presence of DM2 increases significantly the risk of cardiovascular events, chronic kidney disease (CKD), and premature death3,4 and as its prevalence increases it is expected to rise the incidence of microvascular and macrovascular complications.5 Until the last decade, the control of blood glucose, blood pressure, dyslipidemia, and the use of inhibitors of the renin-angiotensin system (iSRA) have been the only strategies available to reduce cardiovascular and renal risk in this population
Chawla MK, Guzowski JF, Ramirez-Amaya V, Lipa P, Hoffman KL, Marriott LK, et al
From the moment I walked into the clinic, I felt welcomed and understood
As serum TG levels in all included samples were less than 4.5 mmol/L, the low-density lipoprotein-cholesterol (LDL-C) levels were calculated according to the Friedewald equation [45]
Blood glucose monitoring should increase in frequency during the microdosing titration phase
.jpg)
